Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.10
TROV's Cash to Debt is ranked higher than
51% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. TROV: 4.10 )
Ranked among companies with meaningful Cash to Debt only.
TROV' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 26.84 Max: No Debt
Current: 4.1
Equity to Asset 0.68
TROV's Equity to Asset is ranked higher than
61% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TROV: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
TROV' s Equity to Asset Range Over the Past 10 Years
Min: -9.76  Med: 0.24 Max: 0.75
Current: 0.68
-9.76
0.75
F-Score: 4
Z-Score: 2.56
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -8100.64
TROV's Operating margin (%) is ranked lower than
97% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. TROV: -8100.64 )
Ranked among companies with meaningful Operating margin (%) only.
TROV' s Operating margin (%) Range Over the Past 10 Years
Min: -8074.76  Med: -3074.99 Max: -1077.56
Current: -8100.64
-8074.76
-1077.56
Net-margin (%) -8804.81
TROV's Net-margin (%) is ranked lower than
97% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.57 vs. TROV: -8804.81 )
Ranked among companies with meaningful Net-margin (%) only.
TROV' s Net-margin (%) Range Over the Past 10 Years
Min: -8776.68  Med: -3565.23 Max: -867.83
Current: -8804.81
-8776.68
-867.83
ROE (%) -89.51
TROV's ROE (%) is ranked lower than
81% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.04 vs. TROV: -89.51 )
Ranked among companies with meaningful ROE (%) only.
TROV' s ROE (%) Range Over the Past 10 Years
Min: -104.97  Med: -99.84 Max: -96.39
Current: -89.51
-104.97
-96.39
ROA (%) -51.47
TROV's ROA (%) is ranked lower than
73% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.95 vs. TROV: -51.47 )
Ranked among companies with meaningful ROA (%) only.
TROV' s ROA (%) Range Over the Past 10 Years
Min: -288.72  Med: -60.85 Max: -51.11
Current: -51.47
-288.72
-51.11
ROC (Joel Greenblatt) (%) -1668.55
TROV's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. TROV: -1668.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TROV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8320.86  Med: -2344.73 Max: -1469.61
Current: -1668.55
-8320.86
-1469.61
Revenue Growth (3Y)(%) -29.30
TROV's Revenue Growth (3Y)(%) is ranked lower than
83% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. TROV: -29.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TROV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.3  Med: -26.00 Max: -17.8
Current: -29.3
-29.3
-17.8
EBITDA Growth (3Y)(%) 3.10
TROV's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. TROV: 3.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TROV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.9  Med: 3.10 Max: 45.9
Current: 3.1
-2.9
45.9
EPS Growth (3Y)(%) 5.70
TROV's EPS Growth (3Y)(%) is ranked higher than
58% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. TROV: 5.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TROV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.1  Med: 5.70 Max: 47.8
Current: 5.7
-3.1
47.8
» TROV's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TROV Guru Trades in

Q2 2015

TROV Guru Trades in Q2 2015

Jim Simons 132,100 sh (New)
» More
Q3 2015

TROV Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q4 2015

TROV Guru Trades in Q4 2015

First Eagle Investment 376,111 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.49
TROV's P/B is ranked lower than
58% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. TROV: 2.49 )
Ranked among companies with meaningful P/B only.
TROV' s P/B Range Over the Past 10 Years
Min: 1.9  Med: 6.95 Max: 70.71
Current: 2.49
1.9
70.71
P/S 309.22
TROV's P/S is ranked lower than
98% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. TROV: 309.22 )
Ranked among companies with meaningful P/S only.
TROV' s P/S Range Over the Past 10 Years
Min: 85.71  Med: 280.00 Max: 916.43
Current: 309.22
85.71
916.43
Current Ratio 8.34
TROV's Current Ratio is ranked higher than
90% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. TROV: 8.34 )
Ranked among companies with meaningful Current Ratio only.
TROV' s Current Ratio Range Over the Past 10 Years
Min: 0.08  Med: 7.26 Max: 15.13
Current: 8.34
0.08
15.13
Quick Ratio 8.34
TROV's Quick Ratio is ranked higher than
91% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. TROV: 8.34 )
Ranked among companies with meaningful Quick Ratio only.
TROV' s Quick Ratio Range Over the Past 10 Years
Min: 0.08  Med: 7.26 Max: 15.13
Current: 8.34
0.08
15.13
Days Sales Outstanding 115.82
TROV's Days Sales Outstanding is ranked lower than
79% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.21 vs. TROV: 115.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
TROV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.3  Med: 113.39 Max: 140.06
Current: 115.82
74.3
140.06
Days Payable 604.08
TROV's Days Payable is ranked higher than
97% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.98 vs. TROV: 604.08 )
Ranked among companies with meaningful Days Payable only.
TROV' s Days Payable Range Over the Past 10 Years
Min: 604.08  Med: 9402.71 Max: 18201.33
Current: 604.08
604.08
18201.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.68
TROV's Price/Net Cash is ranked higher than
77% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.13 vs. TROV: 2.68 )
Ranked among companies with meaningful Price/Net Cash only.
TROV' s Price/Net Cash Range Over the Past 10 Years
Min: 3.6  Med: 8.81 Max: 77
Current: 2.68
3.6
77
Price/Net Current Asset Value 2.63
TROV's Price/Net Current Asset Value is ranked higher than
70% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.92 vs. TROV: 2.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TROV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.53  Med: 8.48 Max: 69.3
Current: 2.63
3.53
69.3
Price/Tangible Book 2.45
TROV's Price/Tangible Book is ranked higher than
57% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. TROV: 2.45 )
Ranked among companies with meaningful Price/Tangible Book only.
TROV' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.3  Med: 7.54 Max: 49.5
Current: 2.45
3.3
49.5
Price/Median PS Value 1.10
TROV's Price/Median PS Value is ranked lower than
87% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TROV: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
TROV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.03 Max: 1.5
Current: 1.1
0.42
1.5
Earnings Yield (Greenblatt) (%) -37.79
TROV's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. TROV: -37.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TROV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -84.19  Med: 0.00 Max: 0
Current: -37.79
-84.19
0

More Statistics

Revenue(Mil) $0
EPS $ -1.22
Beta0.46
Short Percentage of Float15.64%
52-Week Range $2.85 - 13.58
Shares Outstanding(Mil)29.76

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 46 72
EPS($) -1.23 -0.90 0.25
EPS without NRI($) -1.23 -0.90 0.25

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:AMEX:ONVO, NAS:RDNT, NAS:OXFD, NYSE:ENZ, NAS:TTOO, NAS:HSKA » details
Traded in other countries:XE7A.Germany,
TrovaGene Inc was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a intellectual property portfolio. The Company's developed intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, its property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by its growing patent estate. Its competitors include medical diagnostic companies, of which have financial, technical, and marketing resources greater than its resources.
» More Articles for TROV

Headlines

Articles On GuruFocus.com
Why People Lose Money Investing And What You Can Do About It Jul 29 2015 

More From Other Websites
Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference Apr 28 2016
Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference Apr 28 2016
TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Apr 27 2016
What's in Store for TrovaGene (TROV) this Earnings Season? Apr 27 2016
TrovaGene downgraded by Leerink Partners Apr 26 2016
TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Apr 25 2016
Trovagene Appoints Bill Welch as Chief Executive Officer Apr 25 2016
Trovagene Appoints Bill Welch as Chief Executive Officer Apr 25 2016
Trovagene Gains 3% On Favorable Mention In Medical Journal Apr 15 2016
Patient Case Report Demonstrating the Ability of Trovagene's Precision Cancer Monitoring Platform to... Apr 15 2016
TROVAGENE, INC. Files SEC form 8-K, Other Events Apr 15 2016
Patient Case Report Demonstrating the Ability of Trovagene's Precision Cancer Monitoring Platform to... Apr 15 2016
TrovaGene Inks Strategic Partnership with Stratose, Stock Up Apr 12 2016
TROVAGENE, INC. Files SEC form 8-K, Other Events Apr 11 2016
Trovagene Enters Into Preferred Provider Agreement with Stratose PPO Network Apr 11 2016
Trovagene Enters Into Preferred Provider Agreement with Stratose PPO Network Apr 11 2016
TrovaGene To Present Clinical Data On Its Precision Cancer Monitoring Platform Apr 07 2016
Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the... Apr 07 2016
TROVAGENE, INC. Files SEC form 8-K, Other Events Apr 07 2016
Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the... Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK